Screener
Ionis Pharmaceuticals IONS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Current portion of deferred contract revenue | 73,837 | 73,761 |
| Other current liabilities | 25,149 | 22,738 |
| Total current liabilities | 315,638 | 781,567 |
| Long-term deferred contract revenue | 63,030 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 753,356 | 751,495 |
| 1.75 percent convertible senior notes due 2028, net | 569,255 | 567,830 |
| Liability related to sale of future royalties, net | 562,574 | 551,353 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's total current liabilities?
- Ionis Pharmaceuticals (IONS) reported total current liabilities of $315.64M in Q2 2026.
- How has Ionis Pharmaceuticals's total current liabilities changed year-over-year?
- Ionis Pharmaceuticals's total current liabilities decreased by 64.8% year-over-year, from $897.24M to $315.64M.
- What is the long-term trend for Ionis Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total current liabilities has grown at a 6.0% compound annual growth rate (CAGR), from $583.25M to $781.57M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Ionis Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude